AN2 Therapeutics Expands Epetraborole Development into Phase 2 Trial for Polycythemia Vera
核心洞察
AN2 Therapeutics announced plans to advance oral epetraborole into a Phase 2 proof-of-concept study for adults with phlebotomy-dependent polycythemia vera (搜索), a blood cancer (搜索) affecting approximately 155,000 people in the U.S.
The decision is supported by clinical evidence showing epetraborole consistently demonstrated early, controlled, sustained, and dose-dependent hematocrit reductions across multiple clinical populations including healthy volunteers and NTM lung disease patients.
The Phase 2 trial is expected to begin in the third quarter of 2026 in India, with potential data readouts as early as fourth quarter 2026 and throughout 2027.
AN2 Therapeutics has announced plans to expand development of its oral small molecule epetraborole into a Phase 2 proof-of-concept clinical study for adults with phlebotomy-dependent polycythemia vera (搜索) (PV), marking a significant expansion of the company's boron chemistry platform into hematologic malignancies.
The decision to pursue PV is supported by substantial clinical evidence from multiple trials of oral epetraborole in healthy volunteers and non-PV patients, where the drug consistently demonstrated early, controlled, sustained, and dose-dependent reductions in hematocrit at potentially clinically meaningful levels for PV treatment.
Clinical Evidence Supporting PV Development
Epetraborole's hematological effects have been characterized by several key pharmacodynamic and clinical observations across multiple studies. The compound showed consistent hematocrit reductions across multiple clinical populations, including healthy volunteers and nontuberculous mycobacterial (NTM) lung disease patients, with effects sustained over a six-month treatment period.
The drug demonstrated early onset of hematocrit reduction after dose initiation with durable, stable control and reversibility at treatment cessation. Importantly, epetraborole showed no clinically relevant change in white blood cell counts and minimal change in platelet counts, suggesting selective effects on red blood cell production.
Additional supporting evidence includes demonstrated durable hematocrit reduction in 9-month chronic non-human primate studies and a potentially differentiated mechanism of action, likely acting on globin synthesis (搜索) rather than directly on heme synthesis (搜索).
Addressing Unmet Medical Need
PV is a blood cancer (搜索) characterized by overproduction of red blood cells in the bone marrow. This overproduction increases hematocrit, which can lead to serious medical complications, including arterial and venous thromboembolic events. If untreated, PV can be life-threatening.
Despite available therapies, many patients experience uncontrolled hematocrit levels and persistent symptom burden, requiring long-term management to maintain adequate disease control. PV is estimated to affect approximately 155,000 people in the U.S.
"While current therapies are effective for some patients, many continue to have inadequately controlled hematocrit levels and rely on repeated phlebotomy or injectable treatments," said Stan Gerson, M.D., Hematologist and Oncologist at University Hospitals Cleveland Medical Center and Dean and Professor of Medicine at Case Western Reserve University School of Medicine. "As a chronic illness with no cure, PV carries a persistent risk of thrombosis and a substantial symptom burden. There remains a clear need for additional oral treatment options, including those with novel mechanisms of action, that can help manage hematocrit while minimizing treatment burden and long-term tolerability concerns."
Phase 2 Trial Design and Timeline
The planned Phase 2 study consists of an open-label epetraborole sentinel cohort, an open-label dose optimization cohort for dose selection (Part 1), followed by a double-blind, randomized, placebo-controlled cohort (Part 2), and an optional open-label extension cohort (Part 3).
The study is designed to assess the efficacy of oral epetraborole in phlebotomy-dependent adults with PV and its effect on key hematological variables, to optimize a dose regimen on a by-patient level, to assess safety and tolerability, to assess patient-reported outcomes (PROs) using validated PRO instruments, and to assess other key hematological parameters.
AN2 is currently proceeding through the regulatory clearance process and anticipates initiating the Phase 2 trial in India in the third quarter of 2026. The Company expects to provide periodic public data updates as early as the fourth quarter of 2026, subject to regulatory clearance and enrollment progress.
Epetraborole's Mechanism and Safety Profile
Epetraborole is a boron-containing, orally available, small molecule that has shown dose and exposure-dependent decreases in hematocrit. Evidence suggests that it operates by reducing production of early-stage erythrocytes (red blood cells) while sparing other cell lineages in the marrow, including white blood cells and platelets.
Epetraborole's clinical data package supporting evaluation in PV is comprehensive, including 10 Phase 1 studies, two Phase 2 studies, and a Phase 2/3 study in NTM lung disease. The drug has been generally well tolerated in prior trials at doses anticipated for PV and, to date, no tolerability barriers to long-term use have been identified.
"We believe epetraborole may offer a differentiated hematological profile that combines hematocrit control via red-cell selectivity, early onset, titratability and oral delivery, attributes that could address key treatment objectives in polycythemia vera (搜索) and offer patients a new therapeutic option where current approaches fall short," said Eric Easom, Co-Founder, Chairman, President and CEO of AN2 Therapeutics.
Broader Pipeline Impact
This PV program represents one of three proof-of-concept catalysts AN2 believes it is well positioned to achieve in the next two years. The company is also advancing a Phase 2 investigator-initiated trial of epetraborole in M. abscessus complex lung disease (搜索), with enrollment expected to begin in the first quarter of 2026 and topline results anticipated in late 2027.
Additionally, AN2's Chagas disease (搜索) program is progressing as the Phase 1 first-in-human trial of oral AN2-502998 nears completion with initial clinical data expected in the first quarter of 2026. The company plans to initiate a Phase 2 proof-of-concept study in patients with chronic Chagas disease in 2026 pending results.
The company remains on track to advance two boron-based oncology compounds into development in 2026, further demonstrating the versatility of its boron chemistry platform. A March 2026 private placement has extended the company's runway into 2029.